Erlotinib (Tarceva): an update on the clinical trial program
RS Herbst - Seminars in oncology, 2003 - Elsevier
Erlotinib HCI (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
quinazoline-based agent that competes with adenosine triphosphate for binding with the …
quinazoline-based agent that competes with adenosine triphosphate for binding with the …
Preclinical studies with erlotinib (Tarceva)
RW Akita, MX Sliwkowski - Seminars in oncology, 2003 - Elsevier
Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
Erlotinib (Tarceva®): a promising drug targeting epidermal growth factor receptor tyrosine kinase
AM Bulgaru, S Mani, S Goel… - Expert review of …, 2003 - Taylor & Francis
Overexpression of the epidermal growth factor receptor (EGFR) is correlated with a poor
prognosis in several human malignancies. In addition, cancers overexpressing EGFR …
prognosis in several human malignancies. In addition, cancers overexpressing EGFR …
[HTML][HTML] Erlotinib (tarceva) for the treatment of non–small-cell lung cancer and pancreatic cancer
CM Rocha-Lima, LE Raez - Pharmacy and Therapeutics, 2009 - ncbi.nlm.nih.gov
Erlotinib (Tarceva) is a small-molecule, orally dosed, anti-cancer drug that inhibits the
epidermal growth factor receptor. Randomized, controlled clinical studies have …
epidermal growth factor receptor. Randomized, controlled clinical studies have …
Targeting HER1/EGFR in cancer therapy: experience with erlotinib
G Giaccone - Future Oncology, 2005 - Taylor & Francis
Research into the role of the human epidermal receptor growth factor receptor 1/epidermal
growth factor receptor (HER1/EGFR) in tumorigenesis has generated a new class of …
growth factor receptor (HER1/EGFR) in tumorigenesis has generated a new class of …
Erlotinib Hydrochloride
LA Sorbera, J Castaner, JS Silvestre… - Drugs of the Future, 2002 - access.portico.org
The epidermal growth factor receptor (EGFR) is a type 1 receptor tyrosine kinase that is
involved in the modulation of cellular differentiation and is overexpressed in many types of …
involved in the modulation of cellular differentiation and is overexpressed in many types of …
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy
M Tiseo, C Gridelli, S Cascinu, L Crinò, FV Piantedosi… - Lung Cancer, 2009 - Elsevier
BACKGROUND: Erlotinib demonstrated significantly prolonged survival versus placebo in
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …
A review of erlotinib–an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor
R Iyer, A Bharthuar - Expert opinion on pharmacotherapy, 2010 - Taylor & Francis
Importance of the field: The epidermal growth factor receptor (EGFR) is a cell surface
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …
Erlotinib in cancer treatment
MA Bareschino, C Schettino, T Troiani, E Martinelli… - Annals of oncology, 2007 - Elsevier
The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase (TK)
receptor that is frequently expressed in many epithelial tumors. The signaling pathways of …
receptor that is frequently expressed in many epithelial tumors. The signaling pathways of …
Erlotinib: preclinical investigations.
M Hidalgo - Oncology (Williston Park, NY), 2003 - europepmc.org
Erlotinib (Tarceva) is an orally available selective small-molecule inhibitor of HER1/EGFR
tyrosine kinase with a 50% inhibitory concentration of 2 nM for purified tyrosine kinase. This …
tyrosine kinase with a 50% inhibitory concentration of 2 nM for purified tyrosine kinase. This …